AstraZeneca's (AZN) Phase III FALCON Trial of Fulvestrant vs. Anastrozole Met Primary Endpoint
Tweet Send to a Friend
AstraZeneca (NYSE: AZN) announced positive results from the Phase III FALCON trial comparing fulvestrant 500mg to anastrozole 1mg for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
